Zalicus Inc (ZLCS) 0.90 $ZLCS
Zalicus Reports Financial Results for the First Quarter 2014
Business Wire - Fri May 09, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the first quarter ended March 31, 2014.
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Zalicus Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Epirus Biopharmaceuticals
Business Wire - Mon Apr 28, 3:38PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Zalicus, Inc. ("Zalicus"
(NasdaqCM: ZLCS) related to the merger with Epirus Biopharmaceuticals for shareholders. Under the terms of the definitive agreement, Zalicus shareholders will own an unknown percentage of the combined company subject to adjustment based on the level of Zalicus' net cash at closing.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Zalicus, Inc. and Its Board of Directors In Connection With the Sale of the Company to Epirus Biopharmaceuticals, Inc.
Business Wire - Wed Apr 23, 2:30PM CDT
Levi & Korsinsky is investigating the Board of Directors of Zalicus, Inc. ("Zalicus" or "the Company" (NasdaqCM:ZLCS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Epirus Biopharmaceuticals.
Stock to Watch: Zalicus Down 5.8% (ZLCS)
Comtex SmarTrend(R) - Mon Apr 21, 12:45PM CDT
Zalicus (NASDAQ:ZLCS) is one of today's worst performing low-priced stocks, down 5.8% to $1.14 on 1.0x average daily volume. Zalicus has traded 832,000 shares thus far today, vs. average volume of 794,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.2%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc.
Business Wire - Wed Apr 16, 3:50PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Zalicus, Inc. ("Zalicus" or the "Company" (NasdaqCM: ZLCS) and other violations of state law by the board of directors of Zalicus relating to the proposed merger of the Company with Epirus Biopharmraceuticals, Inc. ("Epirus" .
Most active Nasdaq-traded stocks
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Zalicus, Inc. - ZLCS
PR Newswire - Wed Apr 16, 11:51AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Zalicus, Inc. ("Zalicus" or the "Company" (Nasdaq: ZLCS) relating to the proposed merger with Epirus Biopharmaceuticals, Inc. ("Epirus" .
Stock to Watch: Zalicus Up 39.8% (ZLCS)
Comtex SmarTrend(R) - Wed Apr 16, 10:09AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 39.8% to $1.44 on 25.1x average daily volume. Zalicus has traded 9.0 million shares thus far today, vs. average volume of 360,000 shares per day. The stock has outperformed the Dow (39.8% to the Dow's 0.4%) and outperformed the S&P 500 (39.8% to the S&P's 0.3%) during today's trading.
Why Zalicus (ZLCS) Stock Is Soaring Today
at The Street - Wed Apr 16, 9:47AM CDT
Zalicus (ZLCS) soared Wednesday after the biopharmaceutical company announced it would merge with Epirus Biopharmaceuticals. After the all-stock transaction closes, Zalicus will be known as Epirus and will operate under the latter company's...
Epirus Closes $36 Million Series B Financing
Business Wire - Wed Apr 16, 6:01AM CDT
Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that it has closed a $36 million Series B financing round led by Livzon Mabpharm, Inc. Other investors participating in this round include Adage Capital, Greenwoods Investment, Gibralt US, Inc., Monashee Capital Partners LP, and an investment affiliate of Mousse Partners, as well as existing investors TPG Biotech(R), Montreux Equity Partners and 5AM Ventures. In conjunction with the financing, Daotian Fu, Ph.D., CEO of Livzon Mabpharm, Inc., joined the Epirus board of directors. Leerink Partners LLC acted as a placement agent for the transaction.
Epirus and Zalicus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus closes $36 million Series B financing round
Zalicus and Epirus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus Closes $36 Million Series B Financing Round
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
Hot Stock: Zalicus, Shares Gain 11.5% (ZLCS)
Comtex SmarTrend(R) - Wed Jan 22, 10:11AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 11.5% to $2.14 on 3.1x average daily volume. Thus far today, Zalicus has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (25.9% to the Dow's -0.4%) and outperformed the S&P 500 (25.9% to the S&P's -0.1%) during today's trading.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
Zalicus Reports Financial Results for the First Quarter 2014
Business Wire - Fri May 09, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the first quarter ended March 31, 2014.
Inflammatory Pain - Pipeline Review, H1 2014: 43 Company and 68 Drug Profiled
M2 - Wed May 07, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxzwlh/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - A2M Pharma GmbH - AbbVie Inc. - Adynxx, Inc. - AnaMar AB - Anavex Life Sciences Corp. - AngioChem Inc. - Aniona ApS - Array BioPharma Inc. - Asahi Kasei Pharma Corp. - AskAt Inc. - AstraZeneca PLC - Biousian Biosystems, Inc. - Boehringer Ingelheim GmbH - CLL Pharma - DiverDrugs, S.L. - Evotec AG - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Hydra Biosciences, Inc. - RaQualia Pharma Inc. - Relevare Pharmaceuticals Ltd. - Shionogi & Co., Ltd. - Sunovion Pharmaceuticals Inc. - Takeda Pharmaceutical Company Limited - Theralpha SAS - Upsher-Smith Laboratories, Inc. - Winston Pharmaceuticals, Inc. - Zalicus Inc. - Ziarco Pharma Ltd Drug Profiles: - minocycline - grapiprant - AN-721 - ZPL-3893787 - Z-944 - lidocaine - S-120083 - SYN-1002 - Small Molecule To Antagonise P2X3 and P2X2/3 - OX-MPI - nNOS/iNOS - HC-030031 - zucapsaicin - TrkA Program - ANAVEX-1079 - ANG-2002 - AMAP-102 - RQ-00000008 - GBR-900 - CDK9 Inhibitors - Neu-P12 - CNSB-002 - CNSB-006 - AK-106 - Z-212 - PLX Cells For Neuropathic And Inflammatory Pain - THA-902 - Conolidine - AYX-3 - Project MITRA For more information visit http://www.researchandmarkets.com/research/zx...atory_pain
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Zalicus Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Epirus Biopharmaceuticals
Business Wire - Mon Apr 28, 3:38PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Zalicus, Inc. ("Zalicus"
(NasdaqCM: ZLCS) related to the merger with Epirus Biopharmaceuticals for shareholders. Under the terms of the definitive agreement, Zalicus shareholders will own an unknown percentage of the combined company subject to adjustment based on the level of Zalicus' net cash at closing. INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Zalicus, Inc. and Its Board of Directors In Connection With the Sale of the Company to Epirus Biopharmaceuticals, Inc.
Business Wire - Wed Apr 23, 2:30PM CDT
Levi & Korsinsky is investigating the Board of Directors of Zalicus, Inc. ("Zalicus" or "the Company"
(NasdaqCM:ZLCS) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Epirus Biopharmaceuticals. Stock to Watch: Zalicus Down 5.8% (ZLCS)
Comtex SmarTrend(R) - Mon Apr 21, 12:45PM CDT
Zalicus (NASDAQ:ZLCS) is one of today's worst performing low-priced stocks, down 5.8% to $1.14 on 1.0x average daily volume. Zalicus has traded 832,000 shares thus far today, vs. average volume of 794,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.2%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc.
Business Wire - Wed Apr 16, 3:50PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Zalicus, Inc. ("Zalicus" or the "Company"
(NasdaqCM: ZLCS) and other violations of state law by the board of directors of Zalicus relating to the proposed merger of the Company with Epirus Biopharmraceuticals, Inc. ("Epirus" . Most active Nasdaq-traded stocks
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Zalicus, Inc. - ZLCS
PR Newswire - Wed Apr 16, 11:51AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Zalicus, Inc. ("Zalicus" or the "Company"
(Nasdaq: ZLCS) relating to the proposed merger with Epirus Biopharmaceuticals, Inc. ("Epirus" . Stock to Watch: Zalicus Up 39.8% (ZLCS)
Comtex SmarTrend(R) - Wed Apr 16, 10:09AM CDT
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 39.8% to $1.44 on 25.1x average daily volume. Zalicus has traded 9.0 million shares thus far today, vs. average volume of 360,000 shares per day. The stock has outperformed the Dow (39.8% to the Dow's 0.4%) and outperformed the S&P 500 (39.8% to the S&P's 0.3%) during today's trading.
Why Zalicus (ZLCS) Stock Is Soaring Today
at The Street - Wed Apr 16, 9:47AM CDT
Zalicus (ZLCS) soared Wednesday after the biopharmaceutical company announced it would merge with Epirus Biopharmaceuticals. After the all-stock transaction closes, Zalicus will be known as Epirus and will operate under the latter company's...
Epirus Closes $36 Million Series B Financing
Business Wire - Wed Apr 16, 6:01AM CDT
Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced that it has closed a $36 million Series B financing round led by Livzon Mabpharm, Inc. Other investors participating in this round include Adage Capital, Greenwoods Investment, Gibralt US, Inc., Monashee Capital Partners LP, and an investment affiliate of Mousse Partners, as well as existing investors TPG Biotech(R), Montreux Equity Partners and 5AM Ventures. In conjunction with the financing, Daotian Fu, Ph.D., CEO of Livzon Mabpharm, Inc., joined the Epirus board of directors. Leerink Partners LLC acted as a placement agent for the transaction.
Epirus and Zalicus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus closes $36 million Series B financing round
Zalicus and Epirus Announce Merger Agreement
Business Wire - Wed Apr 16, 6:01AM CDT
--Epirus Closes $36 Million Series B Financing Round
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Zalicus to Present at AACR 2014 Annual Meeting
Business Wire - Tue Apr 01, 7:30AM CDT
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS(TM)) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations.
Zalicus Reports Financial Results for the Fourth Quarter and Year-End 2013
Business Wire - Thu Mar 13, 6:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
Canadian Forex Review: C$ Strengthens
Commodity News Service Canada - Commodity News Service Canada, Inc. - Wed Feb 12, 3:44PM CST
The Canadian dollar strengthened against the US dollar on Wednesday amid positive Chinese trade data, analysts said.
Hot Stock: Zalicus, Shares Gain 11.5% (ZLCS)
Comtex SmarTrend(R) - Wed Jan 22, 10:11AM CST
Zalicus (NASDAQ:ZLCS) is one of today's best performing low-priced stocks, up 11.5% to $2.14 on 3.1x average daily volume. Thus far today, Zalicus has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (25.9% to the Dow's -0.4%) and outperformed the S&P 500 (25.9% to the S&P's -0.1%) during today's trading.
3 Stocks Under $10 in Breakout Territory
at The Street - Wed Jan 22, 6:00AM CST
These under-$10 stocks are within range of triggering major breakout trades.
